Effect of tumor necrosis factor α inhibition on CD28 surface expression on CD4+ T cells

Gerli, Roberto; Bocci, Elena Bartoloni; Shoenfeld, Yehuda

doi:10.1002/art.22073

Cited by 6 publications

(2 citation statements)

References 11 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The beneficial effect of anti‐TNF‐α may be exerted, at least in part, by activation of fibrinolytic system, which is usually inhibited in subjects with chronic inflammatory disorders 63 . In addition, RA treatment with these agents is able to reduce the number of proatherosclerotic circulating CD4+CD28– T cells 36,64,65 and may improve insulin resistance and lipid profiles 58,66 …”

Section: Possible Effects Of the Antirheumatic Therapy On CV Risk In Ramentioning

confidence: 99%

Precocious Atherosclerosis in Rheumatoid Arthritis

Gerli

Sherer

Bocci

et al. 2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The risk of cardiovascular (CV) disease increases in patients with rheumatoid arthritis (RA). This is due to a number of different triggers including traditional and disease-related factors. Among established risk factors for CV disease, smoking may exert a more dangerous effect on arterial wall in RA than in the general population by a synergic effect with inflammatory processes of the disease. Although persistent inflammation and immune dysregulation of RA may contribute to favor other well-known CV risk factors, such as dyslipidemia, it is now clear that the disease itself represents an independent risk factor for CV disease by the action of RA chronic inflammatory process as well as humoral and cell-mediated immune mechanisms. There is evidence that CV risk is associated with severity and extension of the disease and it is of interest the fact that the presence of circulating anticyclic citrullinated peptide antibodies appears to be associated with stronger evidence of subclinical atherosclerosis in RA.

show abstract

Section: Possible Effects Of the Antirheumatic Therapy On CV Risk In Ramentioning

confidence: 99%

Precocious Atherosclerosis in Rheumatoid Arthritis

Gerli

Sherer

Bocci

et al. 2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…There are limited data also on the effect of other biological therapies on the number of circulating CD28-T lymphocytes in RA. Studies in small numbers of patients have shown that infliximab may decrease the number of circulating CD4+CD28-lymphocytes 17,18 . However, there was no proof that such a decrease was correlated with clinical response.…”

Section: Discussionmentioning

confidence: 99%

Baseline Numbers of Circulating CD28-negative T Cells May Predict Clinical Response to Abatacept in Patients with Rheumatoid Arthritis

Scarsi¹,

Ziglioli²,

Airò³

2011

J Rheumatol

View full text Add to dashboard Cite

show abstract

Cardiovascular Risk in Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Disorders: a Suggested Model of Preventive Strategy

Bartoloni

Alunno

Bistoni

et al. 2011

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The pathogenesis of accelerated cardiovascular damage commonly characterizing patients affected by systemic chronic inflammatory and autoimmune rheumatic disorders is quite complex and still not fully clarified. However, it is well accepted that a strong relationship between multiple factors, including both traditional cardiovascular risk factors and disease-related inflammatory and autoimmune mechanisms, may in part explain the precocious atherosclerotic vessel damage and the increased incidence of cardiovascular events. Nevertheless, although several recent studies focused their attention on the investigation of these complex mechanisms, data regarding possible preventive strategies aimed to reduce long-term cardiovascular risk in these subjects are still lacking and not conclusive. In this setting, the early introduction of evidence-based preventive measures for the correct management of patients with systemic autoimmune disorders would be of extreme importance to reduce subclinical atherosclerosis incidence and possible major cardiovascular events.

show abstract

Effect of tumor necrosis factor α inhibition on CD28 surface expression on CD4+ T cells

Cited by 6 publications

References 11 publications

Precocious Atherosclerosis in Rheumatoid Arthritis

Precocious Atherosclerosis in Rheumatoid Arthritis

Baseline Numbers of Circulating CD28-negative T Cells May Predict Clinical Response to Abatacept in Patients with Rheumatoid Arthritis

Cardiovascular Risk in Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Disorders: a Suggested Model of Preventive Strategy

Contact Info

Product

Resources

About